$CORT (-3,5%)

Sometimes it's important to keep calm and just stay invested. I'm just annoyed that I didn't buy more. But I don't want to complain on a day like this. Always stay modest.

🧬 Summary of the report

🚀 Share reaction

• The share of Corcept Therapeutics (CORT) jumped by 45 % upwards.
• This was triggered by the success of the phase 3 trial ROSELLA for the drug Relacorilant against platinum-resistant ovarian cancer.

🩺 Study results

• Primary endpoint achieved:
  Overall survival (OS).
• Risk of death decreased by 35 % with combination Relacorilant + Nab-Paclitaxel vs. chemotherapy alone.
• Median overall survival:
• Combination: 16.0 months
• Monotherapy: 11.9 months → +4.1 months advantage

• It was previously reported that the second primary endpoint was also achieved: Progression-free survival (PFS) with 30 % lower risk for disease progression.

🧪 Safety

• Side effects were comparable with standard therapy.
• No new safety concerns → good tolerability.

🏛️ Regulatory status

• FDA is reviewing the approval application, decision date: July 11, 2026.
• EMA is also reviewing a marketing authorization.

🔭 Pipeline outlook

• Relacorilant is also being investigated in studies on other solid tumors: platinum-sensitive ovarian cancer, endometrial, cervical, pancreatic and prostate cancer.